Patient & Caregiver Resources:Insights & News
- Letter to the Duchenne Community, November 14, 2023
- Clinical Leader Article: New Advancement Toward the First Primary Endpoint Qualification of a Digital Endpoint for Duchenne, April 27, 2023
- Cell & Gene Article: Project Orbis For Cell & Gene Therapies Gathers Momentum, April 25, 2023
- Letter to the Duchenne Community: IGNITE DMD Phase I/II Clinical Trial and Business Update, March 23, 2023
- Open letter to the Duchenne Community, December 5, 2022
- Letter to the Duchenne Community: Strategic Update, September 30, 2022
- Letter to the Duchenne Community: Organizational Update to Advance Development of Duchenne Gene Therapy Pipeline Programs, April 27, 2022
- Letter to the Duchenne Community: Data and IGNITE DMD Phase I/II Clinical Trial Update, March 14, 2022
- Biotech 2050 Podcast: Episode 87 - Dr. Joel Schneider on Solid’s Patient-Centric Approach to Gene Therapy in Duchenne, February 1, 2022
- Letter to the Duchenne Community: IGNITE DMD Phase I/II Clinical Trial and 2022 Priorities, January 13, 2022
- Letter to the Duchenne Community: IGNITE DMD Phase I/II Clinical Trial and Pipeline Update, November 3, 2021
- Letter to the Duchenne Community: IGNITE DMD Phase I/II Clinical Trial and R&D Pipeline Development Update, August 16, 2021
- Letter to the Duchenne Community: IGNITE DMD Phase I/II Clinical Trial and Pipeline Update, May 14, 2021
- Letter to the Duchenne Community: Data and IGNITE DMD Clinical Trial Update, March 15, 2021
- Letter to the Duchenne Community: FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial, October 1, 2020
- Letter to the Duchenne Community: Update on SGT-001 Phase I/II Clinical Hold for IGNITE DMD Program, May 7, 2020
- Letter to the Duchenne Community: COVID-19 Update, March 27, 2020
- Letter to the Duchenne Community: Data and IGNITE DMD Clinical Trial Update, March 12, 2020
- Letter to the Duchenne Community: Organizational Changes, January 9, 2020